ClinicalTrials.gg
Active, not recruitingNCT06015737LAVENDERUpdated Nov 12, 2026

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

A Phase 3 interventional study of Anifrolumab and Placebo in Cutaneous Lupus Erythematosus, sponsored by AstraZeneca. Active, not recruiting at 188 sites in 32 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
339
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Lupus Erythematosus, Cutaneous with a site in United States — 10 open to participants now, 16 under way, 7 of them phase 3. Lupus Erythematosus, Cutaneous · United States.

Enrollment
6th of 34
339 · median 46
Started
2024
with 1 other
Phase 3
5 of 39
4 open now
Primary completion
2026-11
later than 3 of 15 live
Registered
27th of 39
by date
Lead sponsor
1 of 39
AstraZeneca

Among the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, this one is the 6th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 3, reaches primary completion later than 3 of the 15 other live ones, and was the 27th registered.

Lupus Erythematosus, Cutaneous

67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.

Browse Lupus Erythematosus, Cutaneous studies →

Open to participants now

10 of the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.

03

Conditions studied

  • Cutaneous Lupus Erythematosus

Keywords

  • Lupus erythematosus
  • Cutaneous lupus erythematosus
  • Anifrolumab
  • Cutaneous Lupus Erythematosus Disease Area Severity Index
  • Subacute lupus
  • Discoid lupus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and confirmed with the following:

    • CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
    • Inadequate response or intolerant to antimalarial therapy.
  • Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
  • use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Key exclusion criteria:

  • History or evidence of suicidal ideation.
  • Severe or life-threatening Systemic lupus erythematosus (SLE).
  • Active SLE or Sjögren's Syndrome.
  • Any active skin conditions other than CLE that may interfere with the study.
  • History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
  • History of recurrent infection requiring hospitalization and IV antibiotics.
  • COVID-19 infection.
  • Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
  • At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total , serum creatinine etc.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
339 participants (actual)

Study arms

  • Experimental
    Anifrolumab

    Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51.

    Combination Product: Anifrolumab

  • Placebo comparator
    Placebo

    Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51.

    Other: Placebo

Interventions

  • Combination productAnifrolumab

    Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).

  • OtherPlacebo

    Matching placebo solution for injection in aPFS.

06

What researchers measure

Primary outcomes

  1. Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score

    The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder.

    Time frame: At Week 24

Secondary outcomes

  1. Change from baseline in total CLASI-A score

    The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE.

    Time frame: At Week 24

  2. Number of participants with CLASI-70 response

    The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder.

    Time frame: At Week 12

  3. Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score

    The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients.

    Time frame: At Week 12

  4. Number of participants with CLASI-50 response

    The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder.

    Time frame: At Week 12 and Week 24

  5. Number of participants who are sustained CLASI-70 responders

    The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated.

    Time frame: Up to Week 52

  6. Serum trough (pre-dose) concentrations of anifrolumab

    The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

    Time frame: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)

  7. Number of participants with positive antidrug antibody

    The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

    Time frame: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)

  8. Percent change from baseline in suppression of the Interferon 21-gene

    The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

    Time frame: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)

  9. Change from baseline in Skindex-29+3 Symptom domain scores

    The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life.

    Time frame: At Week 24

  10. Change from baseline in Skindex-29+3 Emotion domain scores

    The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

    Time frame: At Week 24

  11. Change from baseline in Skindex-29+3 Function domain scores

    The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

    Time frame: At Week 24

  12. Change from baseline in Skindex-29+3 Lupus-Specific domain scores

    The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

    Time frame: At Week 24

  13. Change from baseline in Skindex-29+3 Total score

    The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

    Time frame: At Week 24

  14. Time from IP start date to CLASI-70 response.

    To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE.

    Time frame: From Week 0/Day 1 up to Week 24

  15. Time from IP start date to CLASI-50 response.

    To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE.

    Time frame: From Week 0/Day 1 up to Week 24

Other outcomes

  1. Number of participants with adverse events

    To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE.

    Time frame: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)

07

Study locations

188 sites
  • Research Site
    Phoenix, Arizona 85028, United States
  • Research Site
    Covina, California 91722, United States
  • Research Site
    La Jolla, California 92037, United States
  • Research Site
    Los Angeles, California 90045, United States
  • Research Site
    Los Angeles, California 90089, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    New Haven, Connecticut 06519, United States
  • Research Site
    Washington D.C., District of Columbia 20037, United States
  • Research Site
    Fort Lauderdale, Florida 33309, United States
  • Research Site
    Miami, Florida 33174, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02115-5817, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Bloomfield Hills, Michigan 48302, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Omaha, Nebraska 68198-5885, United States
  • Research Site
    New York, New York 10028, United States
  • Research Site
    Rochester, New York 14642, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Statesville, North Carolina 28625, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Providence, Rhode Island 02903, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Dallas, Texas 75390-8843, United States
  • Research Site
    Charlottesville, Virginia 22903, United States
  • Research Site
    Roanoke, Virginia 24016, United States
  • Research Site
    Ciudad de Buenos Aires, 1221, Argentina
  • Research Site
    Córdoba, 5000, Argentina
  • Research Site
    Córdoba, X5004BAL, Argentina
  • Research Site
    Quilmes, 1878, Argentina
  • Research Site
    San Miguel, 1663, Argentina
  • Research Site
    Kogarah, 3168, Australia
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    Mitcham, 3132, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Woolloongabba, 04102, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Vienna, 1130, Austria
  • Research Site
    Belo Horizonte, 30150-221, Brazil
  • Research Site
    Porto Alegre, 90035903, Brazil
  • Research Site
    Rio de Janeiro, 22470-220, Brazil
  • Research Site
    Salvador, 40150-150, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Sofia, 1463, Bulgaria
  • Research Site
    Sofia, 1528, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Research Site
    Toronto, Ontario M5T 2S8, Canada
  • Research Site
    Osorno, 200025, Chile
  • Research Site
    Santiago, 130021, Chile
  • Research Site
    Santiago, 7500571, Chile
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410011, China
  • Research Site
    Chengdu, 610021, China
  • Research Site
    Chongqing, 400016, China
  • Research Site
    Dongguan, 523059, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Heilongjiang, 150086, China
  • Research Site
    Jinan, 250022, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200443, China
  • Research Site
    Shenzhen, 518020, China
  • Research Site
    Shenzhen, 518052, China
  • Research Site
    Shenzhen, 518053, China
  • Research Site
    Ürümqi, CN-830004, China
  • Research Site
    Zhuzhou, 412007, China
  • Research Site
    Barranquilla, 080020, Colombia
  • Research Site
    Bogotá, 110221, Colombia
  • Research Site
    Aarhus, 641-8510, Denmark
  • Research Site
    Copenhagen, 2100, Denmark
  • Research Site
    Bois-Guillaume, 76031, France
  • Research Site
    Dijon, 21000, France
  • Research Site
    Lyon, 69437, France
  • Research Site
    Montivilliers, 76290, France
  • Research Site
    Nantes, 44000, France
  • Research Site
    Paris, 75010, France
  • Research Site
    Paris, 75013, France
  • Research Site
    Paris, 75014, France
  • Research Site
    Paris, 75970, France
  • Research Site
    Poitiers, 86000, FR, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Bochum, 44791, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Freiburg im Breisgau, 79104, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Kiel, 24105, Germany

Showing the first 100 of 188 sites across 32 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Nov 2026, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 29, 2023
StartActual
Jun 29, 2024
Primary completionActual
Nov 2, 2026
CompletionEst.
Aug 10, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, date precision and site details
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 3 other changes: verification date, date precision and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06015737
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Aug 29, 2023
Start date
Jun 29, 2024
Primary completion
Nov 2, 2026
Completion
Aug 10, 2027 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion